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The therapeutic efficacy of the synthetic
antimalarial drugs in the management of patients
with lupus erythematosus and polymorphous
light eruptions is well established (1—7). Moder-
ately severe rheumatoid arthritis has also
proved responsive to such therapy (8). In an
attempt to explain these beneficial clinical effects
certain light screening, antihistaminic and anti-
inflammatory activities have been considered
(9—11). More recently Lapiere and Van Cauwen-
berge (12) demonstrated a rise in both plasma
and urinary corticoids in a woman with dissemi-
nated lupus erythematosus on chioroquin. It
was the purpose of this study to systematically
investigate the influence of chloroquin and a re-
lated antimalarial on the metabolism of the anti-
inflammatory adrenal corticoids and to report the
preliminary results on a small number of sub-
jects.
CLINICAL MATERIAL
Twelve subject, eight males and four females,
were studied with regard to change in corticoid
metabolism under the influence of synthetic
antimalarial medications.
METHODS
Plasma free 17-hydroxycorticoids were deter-
mined by the method of Eik-Nes (13) using the
Porter-Silber color reaction for the quantitation
of all compounds containing a 20 ketone and 17-21
hydroxyl groups in the steroid nucleus. This
fraction is made up by hydrocortisone to an
extent exceeding 90 per cent in subjects in the
normal state.
"Total" urinary 17-hydroxycorticoids (free
steroids and conjugated glucuronides) were
measured in 24-hour urine specimens, collected
over 8 ml. of a 0.5 per cent solution of thymol in
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glacial acetic acid, by butanol extraction (14)
followed by a modified Porter-Silber reaction
(15).
Twenty-four hour urinary 17-ketosteroids
were determined by a modification of the method
of Callow et at (16) using the Zimmerman
color reaction. Plasma 17-hydroxycorticoids were
fractionated chromatographically by the method
of Bush (17).
EXPERIMENTAL
I. The effect of 8ynthetu antimalaxial therapy on
blood and urine adrenal steroid levels
Twenty to fifty cc. of venous blood were
collected in heparinized tubes always at 9 a.m.
from ten fasting subjects (six males and four
females). The plasma was separated from the
cells immediately and stored in the deep freeze
before being analyzed for plasma free 17-hy-
droxycorticoids. This study was made on two
occasions to serve as baseline controls. Then 8 of
the ten subjects were given 250 mg. of chloroquin
phosphate orally three times a day for six or
seven days. Case 10 received chloroquin 250 mg.
only twice a day for seven days and ease 5 took
Triquin three tablets a day for nine days. The
estimation of free 17-hydroxycorticoids was
repeated on the last day of therapy. 200 micro-
grams of chloroquin in one cc of ethyl alcohol
were dissolved in ten cc of water. This solution was
tested in the same manner as the plasma and it
was found that chioroquin per se did not estimate
as Porter-Silber ehromogens.
Twenty-four hour urine specimens were col-
lected from the ten subjects on two occasions
prior to and once on the last day of the previously
outlined antimalarial therapy and analyzed for
total 17-hydroxycorticoids and 17-ketosteroids.
RESULTS
Eight subjects receiving 250 mg. of chloroquin
phosphate 3 times a day for 6 to 7 days and one
subject receiving 3 tablets of triquin per day for
f Triquin (aralen 65 mgm, plaquinil 50 mgm,
and atabrin 25 mgm) was supplied by the Win-
throp Laboratories.
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TABLE I
Effect of synthetic antimalarials on 17-hydroxycorticoids and 17-ketosteroids
Subject
Urine Blood
% Increase in Blood
l7-Hydroxycorti-
coids above Highest
Control Level
17-hydroxycorticoids l7-ketosterojds l7-hydroxycorticojds micro-
grazn/loo
mg. per 24-hour volume
Control Anti-malarials Control Auti-malarials Control Anti-malarials
1
2
3
4
5
6
7
8
9
10
7.7
5.2
14.9
16.8
5.1
5.5
7.0
12.5
8.7
4.4
11.1
9.1
10.3
8.6
8.4
8.4
2.7
3.6
8.3
7.8
12.9
3.7
8.7
5.7
9.5
5.1
9.3
—
8.9
10.1
10.4
24.2
25.0
7.2
7.0
21.1
22.1
4.2
5.8
17.1
16.1
14.1
11.7
10.2
11.1
4.3
4.5
11.5
10.1
20.9
7.4
22.2
7.0
15.0
8.2
11.4
—
9.9
15.2
16.3
12.9
11.1
10.3
14.9
6.6
7.2
10.7
11.9
10.0
13.8
10.6
—
12.8
14.4
11.5
12.5
14.9
22.8 40
21.0 63
19.0 28
13.3 85
15.0 26
17.4 26
22.8 115
18.3 27
15.1 21
I
14.5 0
9 days showed significant apparent increases in
the plasma free 17-hydroxycorticoids (17-0110).
Casc 10 who received 250 mg. of chioroquin
phosphate only twice a day for 7 days showed no
apparent increase in the blood levels over the
control studies. The rises ranged from 21 % to
115% (Table I) with a mean of 48% for the 10
cases. The mean of two control values of plasma
free 17-0110 was deducted from that obtained
with the patients on antimalarials. These differ-
ences were then used in calculating Fisher's t and
found to be significant at a level of less than 1
per cent probability of being due to chance. In
contrast to the elevation in plasma 17-OHC there
were no significant differences in the total urinary
17-hydroxycorticoids or 17-ketosteroids before
and after treatment. These findings suggest an
apparent rise of plasma free 17-0110 that cannot
be related to increased synthesis of 17-OHC by
the adrenals.
II. The effect of chioroquin phosphate on the
disposal of intravenously administered
hydrocortisone
A fasting baseline for plasma free and urine
total 17-hydroxycorticoids was determined in a
normal young male. The subject was then given
100 mg. of hydrocortisone in 5% alcohol intra-
venously over a hour period. The plasma 17-
hydroxycorticoid levels were determined im-
mediately on completion of the hydrocortisone
infusion, and then at one hour periods for four
hours. The urinary 17-hydroxycorticoids were
tested every four hours for sixteen hours after the
infusion and again at 24 hours. 24 hour urinary
17-ketosteroids were also determined.
Chioroquin phosphate was then taken orally
250 mg. 3 times a day for 10 days and the testing
procedure repeated.
RESULTS
Only two differences between the control
experiment and the one with the patient on
chloroquin (0.75 gm. per day for 10 days) be-
came evident (Table II). A slight elevation of
apparent basal plasma 17-0110 on chloroquin
which, while not significant, agrees with the gen-
eral trend in the experimental group. The clear-
ance of large doses of hydrocortisone from the
plasma was not impaired according to this
experiment. Urinary total 17-0110 during the
first 4 hours on chioroquin were significantly
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TABLE II
Fate of hydrocortisone, 100 mg. infu8ed intravenously from 0 to hour
Blood
Free ll-Hydroxycorticoids
Urine
Total l-Hydroxycorticoids
Urine
17-Ketosteroids
Time microgram/iSO ml. Time (collection period) mgm/volume mgm/24 hours
Control 0
hr.
lhr.
2 hr.
3hr.
4 hr.
10.4
104.0
77.0
52.5
35.5
27.1
0—4 hr.
4—8 hr.
8—l2hr.
12—16 hr.
16—24hr.
12.9
6.8
3.2
0.3
2.3
10.3
Total 25.5
After 10 days on
Chloroquin 0.75
gm/day
0
3 hr.
1 hr.
2 hr.
3 hr.
4 hr.
12.3
112.5
69.2
—
38.9
29.0
0—4 hr.
4—8 hr.
8—12 hr.
12—16 hr.
16—24 hr.
9.0
7.2
3.4
1.7
2.5
11.7
Total 23.8
lower than during a similar period off the drug.
However, subsequent periods on chioroquin
showed definitely higher levels and the total 24
hour excretion was approximately the same.
These findings might be compatible with an
initial delay of the urinary excretion of the
metabolites of hydrocortisone.
III. The effect of chloroquin on the relative propor-
tions of biologically active and inactive
1 7-hydroxycorticoids in plasma
One normal male subject received one gm. of
chioroquin phosphate a day for 4 days and 750
mgm. a day for 3 days by mouth. 17-OHC were
extracted from 50 ml. of plasma and chromato-
graphed by the method of Bush (17). In addition,
the plasma free and urine total and free 17-hydrox-
ycorticoids were compared before and after the
chloroquin therapy.
RESULTS
Changes in 17-hydroxycorticoids are shown
in Table III. Except for a small but significant
rise in plasma free 17-OHC there were no real
changes. The free urinary 17-OIIC did not in-
crease. A direct prompt Vanden Bergh reaction
(bilirubin glucuronide) was 0.1 mg. per 100 ml. of
serum before and after chloroquin and the total
biblirubin remained the same at 0.7 mg. per 100
ml. of serum. The chromatographic studies
showed normal plasma free 17-hydroxycorticoid
levels. There was a trace of tetrahydrocortisone
Treatment 17-ilydroxycorticoids
Day Chloroquin gm. Plasmafree
Urine
free
Urine
total
Per cent
free
0
1—3
4
5
6
7
0
0.25 q.i.d.
0.25 q.i.d.
0.25 t.i.d.
0.25 t.i.d.
0.25 t.i.d.
7.3
8.1
11.0
0.42
0.33
0.23
0.37
13.6
15.8
11.3
11.1
3.1
2.1
2.0
3.3
present which was however within normal limits.
No abnormal steroid substances were found to
account for the apparent rise in the plasma free
17-hydroxycorticoids as determined by the
Porter-Silber reaction.
DISCUSSION
The mechanism or mechanisms of action of the
synthetic antimalarials in lupus erythematosus
and polymorphous light eruptions are not well
understood. Some observers have considered
ultra violet light filtration to be of paramount
importance (9, 18). Though the drugs evidently
do alter at least certain ultra violet responses in
these diseases, the bulk of evidence at present is
against this action being the main therapeutic
effect (19).
In recent years the synthetic antimalarials
have been noted to exhibit relatively potent
anti-inflammatory properties. Studies on phenol
TABLE III
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induced erythema reactions revealed that chioro-
quin increased the latent period and decreased
the intensity of the response (20). Blaich and
Gerlach found that cMoroquin inhibited inflam-
matory reactions, accelerated ulcer healing and
reduced blood vessel permeability in animal
experiments (21). Whitehead and Hager noted
similar anti-inflammatory properties and in
addition demonstrated a marked anti-hyaluroni-
dase action (11). The latter effect was not found
as consistently in human experimentation but
did occur in several subjects (22).
How the synthetic antimalarials depress
inflammation and inhibit erythema reactions is
not clear. The combination of atabrine and chioro-
quin with desoxyribonucleic acid may be of some
importance in the therapy of lupus erythemato-
sus. Haydu postulated that the effect of anti-
malarials in rheumatoid arthritis might be due
to an adenosine triphosphate sparing effect (23).
Others have suggested that these medications
might act by antagonizing the physiological
action of adenosine derivatives since the effects
of adenosine on heart muscle are inhibited by
such drugs (1, 2, 24).
More recently the influence of the synthetic
antimalarial drugs on adrenal cortical steroid
metabolism has received considerable attention.
An increased 17-ketosteroid excretion in subjects
taking atabrine was noted by Nagy and Kocsar
(10). In contrast Lapiere and Cauwenberge
found, in the study of a young woman with
disseminated lupus erythematosus on 0.6 gm. of
chloroquin daily, that the chioroquin therapy
was associated with a decrease in the urinary
17-ketosteroids, a significant increase in the
plasma free and urinary 17-hydroxycorticoids
and a somewhat variable rise in the urinary
glucuronic acid conjugates of the 17-hydroxy-
corticoids (12). In our study we also found that
chioroquin and triquin therapy were associated
with an apparent increase in the plasma free 17-
hydroxycorticoids determined by the Porter-
Silber reaction in 9 of the 10 subjects investi-
gated. This rise ranged from 21% to 115% with
a mean of 48%. However, there was no change
in the urine values for the 17-ketosteroids or the
total 17-hydroxycorticoids. This latter determina-
tion consists of both the free nonreduced active
17-hydroxycorticoids and the reduced biologically
inactive glucuronic acid conjugates.
These findings obtain against any direct
stimulation of the pituitary adrenal system by the
antimalarials since such an effect should be ac-
companied by an increase in the urine as well as
the plasma corticoids. The observations of Nagy
et at of adrenal cortical hypertrophy with in-
creased adrenal lipid production in animals
treated with atabrin might be explained by a
stress reaction due to the relatively high doses
used (25).
Furthermore the apparent elevation in the
plasma free 17-hydroxycorticoids was not as-
sociated with a compensatory fall in cortico-
tropin secretion by the pituitary. This suggests
that the circulating substances responsible for
the rise might be biologically inactive though
evidently unconjugated free tetrahydrocortisone.
This reduced, inactive, but unconjugated corti-
coid has been found in significant amounts in the
plasma of patients with hepatic disease (26).
However, the expected rise in the unconjugated
portion of the urinary 17-hydroxycorticoids was
not seen. In addition, our chromatographic
investigations showed that tetrahydrocortisone
was present in only trace amounts which is
within normal limits. Also, no other abnormal
steroids were noted to account for the apparent
increased plasma 17-hydroxycorticoids demon-
strated by the Porter-Silver reaction. Therefore
we were probably dealing with an artifact, which
might well be a metabolite of choroquin. It is
interesting that this material was evidently not
measured with the urinary 17-hydrocorticoids.
We must conclude then that the increased plasma
levels noted after chloroquin intake did not
represent biologically active corticoids. Thus at
our present state of knowledge we are unable to
correlate the therapeutic effects of the synthetic
antimalarials in lupus erythematosus and other
diseases with adrenal cortical function.
SUMMARY
1. In our preliminary study, of 10 subjects
given chioroquin or an allied antimalarial drug
for 6 to 9 days, 9 showed a significant increase
in the apparent free plasma 17-hydroxycorticoids.
This rise ranged from 21% to 115%. In contrast,
the urinary total 17-hydroxycorticoids and 17-
ketosteroids were unchanged indicating that there
was no increase in adrenal corticoid production.
2. Though an initial delay was noted, the
urinary excretion of intravenously administered
hydrocortisone was essentially unimpared by
chioroquin therapy.
3. The absence of a compensatory pituitary
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inhibition by the apparent increase in free
17-hydroxycorticoids indicated that we were
dealing with a biologically inactive but evidently
unconjugated substance. However, the expected
increase in the unconjugated component of the
urinary 17-hydroxycorticoids was not found.
In addition, our chromatographic studies demon-
strated only a trace of tetrahydrocortisone which
was within normal limits, and no other abnormal
steroids were isolated to account for the apparent
rise in the plasma free 17-hydroxycorticoids.
4. It is concluded that the synthetic antimalar-
ials probably do not act through the pituitary
adrenal system in producing their therapeutic
effects.
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DISCUSSION
DR. STEPHEN ROTHMAN (Chicago, Ill.): If steroids do you believe they are sufficient to exert
there is a significant increase in release of active therapeutic effects?
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DR. JOUN H. EPSTEIN (in closing): In answer
to Dr. Rothman's question, an increase in the
blood 17-hydroxycorticoids in the apparent
range noted in our study would certainly have
some anti-inflammatory effect. The clinical
efficacy of this inhibition would depend on
the severity of the inflammatory reaction. How-
ever, I would like to emphasize that our findings
obtain strongly against the pituitary adrenal
stimulation theory.
